Research Including Patients from Quebec Demonstrated Significant Impact of Genomic Health's Oncotype DX^® in Personalizing Cancer Treatments

REDWOOD CITY, CA, March 30, 2017 /CNW/ - Genomic Health, Inc. (Nasdaq: GHDX) today announced results from 15 Oncotype DX^® studies across 12 countries, providing real-world evidence of the test's ability to change treatment decisions in breast cancer patients. New findings, presented at the 15^th St. Gallen International Breast Cancer Conference in Vienna, included a summary of outcomes from nine studies involving more than 600 early-stage breast cancer patients who underwent neoadjuvant therapy.  Results included from the findings from a key prospective multi-centre study involved the Breast Cancer Centre, Centre Hospitalier de l'Université de Montréal, Quebec, Canada.

The Oncotype DX Breast Recurrence Score^® test was performed on core biopsies in these patients prior to receiving either neoadjuvant chemotherapy or neoadjuvant hormone therapy. The presentation demonstrated that analyzing tumour biology with the Oncotype DX test could identify patients unlikely to benefit from chemotherapy prior to breast cancer surgery (neoadjuvant setting) and more likely to achieve successful clinical response and breast-conserving surgery with neoadjuvant hormone therapy. These results highlight the test's utility in guiding treatment decisions without compromising outcomes.

"This data demonstrates that analyzing tumour biology with Oncotype DX on initial core biopsies in the neoadjuvant setting could be a powerful strategy in guiding treatment decisions," said Dr. André Robidoux, study investigator and Director of the Breast Cancer Centre, Centre Hospitalier de l'Université de Montréal, Quebec, Canada. "Tumour shrinkage is difficult to achieve in patients with oestrogen receptor positive breast cancer, even with chemotherapy. But if we can identify patients who are likely to respond well to hormonal therapy, we can maximize their chances of breast-conserving surgery whilst limiting the impact of treatment side effects on their quality of life." 

The analysis showed that for patients with a Recurrence Score^® result below 25, treatment with neoadjuvant hormonal therapy alone could be an effective treatment strategy to achieve BCS. Such patients could thus potentially avoid chemotherapy without reducing their chances of successful BCS. 

"In this study, researchers also evaluated how well patients accepted treatment choices guided by their Oncotype DX result. This data demonstrated that acceptance was high, underscoring the value of the test in guiding important treatment decisions," said Calvin Chao, M.D., vice president of international medical affairs, Genomic Health. "The Oncotype DX test has been used in clinical practice in Quebec since 2010, and we are pleased to be able to help thousands of patients each year to utilize the technology that has been recognized by all major international clinical guidelines."

About Oncotype DX^®
The Oncotype DX^® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumour in order to optimize cancer treatment decisions. The company's flagship product, the Oncotype DX breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. Additionally, the test predicts the likelihood of recurrence in a pre-invasive form of breast cancer called DCIS. With more than 700,000 patients tested in more than 90 countries, the Oncotype DX tests have redefined personalized medicine by making genomics a critical part of cancer diagnosis and treatment. To learn more about Oncotype DX tests, visit www.OncotypeDX.com or www.MyBreastCancerTreatment.org.

About Genomic Health 
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care by addressing the overtreatment of the disease, one of the greatest issues in healthcare today. With its Oncotype IQ^® Genomic Intelligence Platform, the company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of clinical and genomic big data into actionable results for treatment planning throughout the cancer patient journey, from diagnosis to treatment selection and monitoring. The Oncotype IQ portfolio of genomic tests and services currently consists of the company's flagship line of Oncotype DX gene expression tests that have been used to guide treatment decisions for more than 700,000 cancer patients worldwide. Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the recently launched Oncotype SEQ^® Liquid Select assay. The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland. For more information, please visit, www.GenomicHealth.com and follow the company on Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's quarterly report on Form 10-Q for the year ended December 31, 2016. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, DCIS Score, Oncotype SEQ, and Oncotype IQ are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.

SOURCE Genomic Health, Inc.

To view the original version on PR Newswire, visit: http://www.newswire.ca/en/releases/archive/March2017/30/c7651.html